Related Experiment Video
Updated: May 28, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Clinical Relevance of Atrial Fibrillation in End-Stage Heart Failure Patients Actively Waiting on Heart Transplant
Magda Haum1,2, Ulrich Grabmaier1,2, Antonia Kellnar1,2
1Department of Medicine I, LMU University Hospital, 81377 Munich, Germany.
Insights
In end-stage heart failure patients awaiting heart transplant, atrial fibrillation is not common and rarely causes worsening. Most diagnoses occur before transplant listing, with interventions like ablation and cardioversion proving effective when needed.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Catheter ablation for atrial fibrillation improves outcomes in end-stage heart failure.
- Atrial fibrillation's relevance and the need for intervention in heart failure patients awaiting transplant are hypothesized.
- This study examines atrial fibrillation presentation and management in heart transplant candidates.
Purpose of the Study:
- To describe the clinical presentation of atrial fibrillation (AF) in end-stage heart failure patients awaiting heart transplant.
- To evaluate the management of AF in this specific patient cohort.
- To assess the impact of AF on clinical worsening during the active heart transplant waiting period.
Main Methods:
- Analysis of 31 actively listed heart transplant patients (EUROTRANSPLANT) as of December 31, 2024.
- Exclusion of patients with assist devices, high-urgency status, minors, and those needing multi-organ transplants.
- Review of AF diagnosis timing and management strategies.
Main Results:
- 58% of patients had no AF diagnosis; 42% presented with AF or flutter.
- Most AF diagnoses (69%) occurred before active transplant listing.
- Newly diagnosed AF/flutter during the waiting period (3 patients) were managed with pulmonary vein ablation or electrical cardioversion.
Conclusions:
- Atrial fibrillation is not prevalent in all end-stage heart failure patients awaiting heart transplant.
- AF diagnosis typically precedes the active heart transplant waiting list.
- AF is not a frequent cause of clinical deterioration in patients actively awaiting heart transplantation.
Abstract:
Background: Recent studies have shown that catheter ablation of atrial fibrillation leads to an improvement in mortality and a reduction in hospitalization in patients with end-stage heart failure. It is therefore hypothesized that in an end-stage heart failure population, atrial fibrillation is of great relevance and that interventional therapy is crucial to preventing further progression, especially with the aim of avoiding a heart transplant. In this paper, we describe the clinical presentation of atrial fibrillation and its management in a real end-stage heart failure cohort of patients actively waiting on a heart transplant through EUROTRANSPLANT. Methods: A total of 577 patients have been actively listed for heart transplant in our clinic. Of these, we examined all patients who were actively listed by the key date of 31 December 2024. Patients already treated by assist devices such as the left-ventricular assist device and high-urgency listed patients were excluded, as were minors and patients in need of simultaneous transplantation of other organs in addition to the heart. Results: Thirty-one patients were included in our analysis. In this cohort, 18 patients (58%) had no diagnosis of atrial fibrillation or atrial flutter. A total of 13 patients (42%) presented with atrial fibrillation or flutter: 3/13 (23%) paroxysmal, 8/13 (62%) persistent, 1/13 (8%) permanent atrial fibrillation, and 1/13 (8%) atrial flutter. Moreover, 9/13 (69%) patients with atrial fibrillation had been diagnosed during evaluation and before the active listing period for heart transplant. Only three patients developed atrial fibrillation during the active listing period (two with atypical atrial flutter, one with atrial fibrillation). In those three patients, rhythm control could be achieved: the patient with new-onset atrial fibrillation was treated by pulmonary vein ablation, and in the two patients with newly diagnosed atypical atrial flutter, electrical cardioversion was performed. Conclusions: In our real end-stage heart failure cohort, more than half of the patients do not have atrial fibrillation. Patients diagnosed with atrial fibrillation often receive their diagnosis before they are listed for heart transplant. However, atrial fibrillation is not a common cause of clinical worsening while actively waiting on a heart transplant.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure

